Report Library

All Reports
Diffuse Large B-Cell Lymphoma (DLBCL) KOL Interview – UK

April 21, 2022

A UK-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for DLBCL. Therapies discussed include Polivy, Monjuvi, Zynlonta, CD19-directed CAR-T therapy, and CD20-directed bispecific antibodies. 

If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only)

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357. 

For our disclosures, please read the Biomedtracker Research Standards.

Indications Covered: Diffuse Large B-Cell Lymphoma (DLBCL) - NHL

 Additional Resources:
Back to the top Back to the top